Neuroblastoma Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight's "Neuroblastoma Pipeline Insight 2026" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in the Neuroblastoma pipeline landscape. It covers the Neuroblastoma Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Neuroblastoma Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Neuroblastoma Pipeline? Click here to explore the therapies and trials making headlines @ https://www.delveinsight.com/sample-request/neuroblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Neuroblastoma Pipeline Report
• On January 09, 2026- Merck Sharp & Dohme LLC initiated a study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants with Ewing sarcoma.
• On January 07, 2026- Memorial Sloan Kettering Cancer Center announced a Phase I/II study is to find out if an antibody called Humanized 3F8 (Hu3F8) combined with granulocyte- macrophage colony stimulating factor (GM-CSF) is safe for treating neuroblastoma.
• On January 07, 2026- Novartis Pharmaceuticals conducted a study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.
• DelveInsight's Neuroblastoma Pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Neuroblastoma treatment.
• The leading Neuroblastoma Companies such as INSYS Therapeutics Inc., Hoffmann-La Roche, Endeavor Biomedicines Inc., Novartis Pharmaceuticals, Daiichi Sankyo, Celgene, Cancer Research UK, Cardiff Oncology, Elicio Therapeutics, Merck, Eli Lilly and Company, Pfizer, Adaptimmune, and others.
• Promising Neuroblastoma Therapies such as Eflornithine, Temozolomide, Irinotecan, DFMO, Racotumomab, Bevacizumab, Temozolomide, Topotecan hydrochlorideand others.

Want to know which companies are leading innovation in Neuroblastoma? Dive into the full pipeline insights @ https://www.delveinsight.com/sample-request/neuroblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Neuroblastoma Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Neuroblastoma Pipeline Report also highlights the unmet needs with respect to the Neuroblastoma.

Neuroblastoma Overview
Neuroblastoma is a rare type of cancer that mostly affects babies and young children. It develops from specialised nerve cells (neuroblasts) left behind from a baby's development in the womb. Neuroblastoma most commonly occurs in 1 of the adrenal glands situated above the kidneys, or in the nerve tissue that runs alongside the spinal cord in the neck, chest, tummy or pelvis. It can spread to other organs, such as the bone marrow, bone, lymph nodes, liver and skin. Neuroblastoma is a type of cancer that primarily affects young children and arises from immature nerve cells. Common signs and symptoms include a lump or mass in the abdomen, chest, or neck, often accompanied by pain or swelling. Other symptoms can include fatigue, loss of appetite, weight loss, and fever.

Neuroblastoma Emerging Drugs Profile
• Hu14.18: Essential Pharma
Hu14.18K322A, commonly referred to as Hu14.18, is a humanized anti-GD2 monoclonal antibody developed by Renaissance Pharma for the treatment of high-risk neuroblastoma (HRNB). In April 2025, Essential Pharma announced that it had completed the acquisition of the Renaissance Pharma Ltd. with its lead asset being Hu14.18K322A (Hu14.18). Currently the drug is in Phase II stage of its clinical trial for the treatment of neuroblastoma.

• 67-Cu-SARTATE: Clarity Pharmaceuticals
67Cu-SARTATE is an emerging theranostic radiopharmaceutical specifically designed for the diagnosis and treatment of high-risk neuroblastoma, a particularly aggressive childhood cancer. This compound utilizes copper-67 (67Cu) as a therapeutic agent, complementing its diagnostic counterpart, copper-64 (64Cu), which is used for imaging. The drug has been granted Rare Pediatric Disease Designation and Orphan Drug Designation for the clinical management of neuroblastoma. Currently the drug is in Phase I/II stage of its clinical trial for the treatment of neuroblastoma.

• Alrizomadlin (APG-115): Ascentage Pharma
APG-115 is a potent, orally bioavailable MDM2 inhibitor that binds to human recombinant MDM2 protein with high affinity. Mechanistically, APG-115 interferes the binding of MDM2 oncoprotein with the tumor suppressor P53 protein, leads to increased P53 and P21 protein expression and trigger P53-mediated apoptosis. In addition to its direct tumor-targeting activity, APG-115 plays an important role in immune modulation through its effects on immune cells, tumor cells and multiple cytokines. Alrizomadlin has been granted Orphan Drug Designations by the U.S. FDA for the treatment of gastric cancer, soft-tissue sarcoma, AML, Retinoblastoma, IIB-IV melanoma and Neuroblastoma. Currently the drug is in Phase I stage of its clinical trial for the treatment of Neuroblastoma.

If you're tracking ongoing Neuroblastoma Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ https://www.delveinsight.com/sample-request/neuroblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Neuroblastoma Pipeline report provides insights into:-
• The report provides detailed insights about companies that are developing therapies for the treatment of Neuroblastoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neuroblastoma Treatment.
• Neuroblastoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Neuroblastoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neuroblastoma market.

Neuroblastoma Companies
INSYS Therapeutics Inc., Hoffmann-La Roche, Endeavor Biomedicines Inc., Novartis Pharmaceuticals, Daiichi Sankyo, Celgene, Cancer Research UK, Cardiff Oncology, Elicio Therapeutics, Merck, Eli Lilly and Company, Pfizer, Adaptimmune, and others.

Neuroblastoma Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Neuroblastoma Products have been categorized under various Molecule types such as,
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the Neuroblastoma Pipeline Report covers it all - check it out now @ https://www.delveinsight.com/sample-request/neuroblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Neuroblastoma Pipeline Report
• Coverage- Global
• Neuroblastoma Companies-INSYS Therapeutics Inc., Hoffmann-La Roche, Endeavor Biomedicines Inc., Novartis Pharmaceuticals, Daiichi Sankyo, Celgene, Cancer Research UK, Cardiff Oncology, Elicio Therapeutics, Merck, Eli Lilly and Company, Pfizer, Adaptimmune, and others.
• Neuroblastoma Therapies- Eflornithine, Temozolomide, Irinotecan, DFMO, Racotumomab, Bevacizumab, Temozolomide, Topotecan hydrochlorideand others.
• Neuroblastoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Neuroblastoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the Neuroblastoma Treatment landscape in this detailed analysis @ https://www.delveinsight.com/sample-request/neuroblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. Neuroblastoma: Overview
4. Neuroblastoma Pipeline Therapeutics
5. Neuroblastoma Therapeutic Assessment
6. Neuroblastoma- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. Hu14.18: Essential Pharma
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I)
14. Alrizomadlin (APG-115): Ascentage Pharma
15. Drug profiles in the detailed report.....
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report.....
19. Inactive Products
20. Neuroblastoma Key Companies
21. Neuroblastoma Key Products
22. Neuroblastoma- Unmet Needs
23. Neuroblastoma- Market Drivers and Barriers
24. Neuroblastoma- Future Perspectives and Conclusion
25. Neuroblastoma Analyst Views
26. Neuroblastoma Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.